|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/46 | |
| A61P 1/00 | |||
| A61P 1/16 | |||
| A61K 31/4748 | |||
| A61K 31/497 | |||
| A61K 31/506 |
| (11) | Number of the document | 3419624 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17708341.7 |
| Date of filing the European patent application | 2017-02-20 | |
| (97) | Date of publication of the European application | 2019-01-02 |
| (45) | Date of publication and mention of the grant of the patent | 2021-01-13 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/IB2017/050962 |
| Date | 2017-02-20 |
| (87) | Number | WO 2017/145040 |
| Date | 2017-08-31 |
| (30) | Number | Date | Country code |
| 201662298113 P | 2016-02-22 | US |
| (72) |
LAFFITTE, Bryan, US
BADMAN, Michael, US
CHEN, Jin, US
LINDGREN, Sam, CH
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | METHODS FOR USING FXR AGONISTS |
| METHODS FOR USING FXR AGONISTS |